Edition:
United States

Profile: Fortress Biotech Inc (FBIO.O)

FBIO.O on Consolidated Issue listed on NASDAQ Capital Market

1.04USD
18 Dec 2018
Change (% chg)

$0.03 (+2.97%)
Prev Close
$1.01
Open
$1.01
Day's High
$1.06
Day's Low
$0.96
Volume
493,254
Avg. Vol
267,722
52-wk High
$5.54
52-wk Low
$0.83

Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies.

Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio, National Holdings Corp and Tamid Bio, Inc.

Company Address

Fortress Biotech Inc

2 Gansevoort St Fl 9
NEW YORK   NY   10014-1667
P: +1781.6524500
F: +1781.6524545

Company Web Links